The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Therapeutic potentials of gene silencing by RNA interference: Principles, challenges, and new strategies
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429 · cited 2×
“In 1998, double stranded RNAs were firstly discovered to be the silencing effectors to regulate gene functions in Caenorhabditis elegans (Fire et al., 1998).”
BackgroundDuplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
John, B., Enright, A. J., Aravin, A., Tuschl, T., Sander, C., & Marks, D. S. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020363 · Cited by 3,796 · cited 2×
“Unlike siRNAs and shRNA, miRNAs are only partially complementary to their target mRNAs' 3′ untranslated region (UTR), regulating their targets via all four Ago proteins (AGO1–4) (John et al., 2004).”
BackgroundFactors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Block copolymer micelles for drug delivery: design, characterization and biological significance
Kataoka, K., Harada, A., & Nagasaki, Y. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00124-1 · Cited by 3,506
A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants
Hamilton, A. J., & Baulcombe, D. C. (1999) · Science · doi:10.1126/science.286.5441.950 · Cited by 3,041
Argonaute2 is the catalytic engine of mammalian RNAi
Liu, J., Carmell, M. A., Rivas, F. V., Marsden, C. G., Thomson, J. M., Song, J.-J., Hammond, S. M., Joshua-Tor, L., & Hannon, G. J. (2004) · Science · doi:10.1126/science.1102513 · Cited by 2,796
Zamore, P. D., Tuschl, T., Sharp, P. A., & Bartel, D. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80620-0 · Cited by 2,676
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Microneedles for drug and vaccine delivery
Kim, Y.-C., Park, J.-H., & Prausnitz, M. R. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.04.005 · Cited by 1,760
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Crystal Structure of Argonaute and Its Implications for RISC Slicer Activity
Song, J.-J., Smith, S. K., Hannon, G. J., & Joshua-Tor, L. (2004) · Science · doi:10.1126/science.1102514 · Cited by 1,470
Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi
Martinez, J., Patkaniowska, A., Urlaub, H., Lührmann, R., & Tuschl, T. (2002) · Cell · doi:10.1016/s0092-8674(02)00908-x · Cited by 1,459
Argonaute proteins: key players in RNA silencing
Hutvagner, G., & Simard, M. J. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2321 · Cited by 1,359
Hornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,232
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E. S., Busini, V., Hossain, N., Bacallado, S. A., Nguyen, D. N., Fuller, J., Alvarez, R., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1402 · Cited by 1,150
RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells
Yu, J.-Y., DeRuiter, S. L., & Turner, D. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092143499 · Cited by 1,039
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity
Jackson, A. L., Burchard, J., Schelter, J., Chau, B. N., Cleary, M., Lim, L., & Linsley, P. S. (2006) · RNA · doi:10.1261/rna.25706 · Cited by 956
Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells
Lee, N. S., Dohjima, T., Bauer, G., Li, H., Li, M.-J., Ehsani, A., Salvaterra, P., & Rossi, J. (2002) · Nature Biotechnology · doi:10.1038/nbt0502-500 · Cited by 953
3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets
Birmingham, A., Anderson, E. M., Reynolds, A., Ilsley-Tyree, D., Leake, D., Fedorov, Y., Baskerville, S., Maksimova, E., Robinson, K., Karpilow, J., et al. (2006) · Nature Methods · doi:10.1038/nmeth854 · Cited by 920
RNAi therapeutics: Principles, prospects and challenges
Aagaard, L., & Rossi, J. J. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.005 · Cited by 895
A novel cationic liposome reagent for efficient transfection of mammalian cells
Gao, X., & Huang, L. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)91366-k · Cited by 847
Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing
Jackson, A. L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J. M., Lim, L., Karpilow, J., Nichols, K., et al. (2006) · RNA · doi:10.1261/rna.30706 · Cited by 789
Li, J., & Loh, X. J. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.02.011 · Cited by 787
siRNA-directed inhibition of HIV-1 infection
Novina, C. D., Murray, M. F., Dykxhoorn, D. M., Beresford, P. J., Riess, J., Lee, S.-K., Collman, R. G., Lieberman, J., Shankar, P., & Sharp, P. A. (2002) · Nature Medicine · doi:10.1038/nm725 · Cited by 773
Modulation of HIV-1 replication by RNA interference
Jacque, J.-M., Triques, K., & Stevenson, M. (2002) · Nature · doi:10.1038/nature00896 · Cited by 719
Microneedle-based drug delivery systems: Microfabrication, drug delivery, and safety
Donnelly, R. F., Singh, T. R. R., & Woolfson, A. D. (2010) · Drug Delivery · doi:10.3109/10717541003667798 · Cited by 708
Epigenetic reprogramming in cancer
Suvà, M. L., Riggi, N., & Bernstein, B. E. (2013) · Science · doi:10.1126/science.1230184 · Cited by 706
In vivo imaging of siRNA delivery and silencing in tumors
Medarova, Z., Pham, W., Farrar, C., Petkova, V., & Moore, A. (2007) · Nature Medicine · doi:10.1038/nm1486 · Cited by 697
Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis.
Lee, R. J., & Low, P. S. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41848-5 · Cited by 692
Harper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., & Davidson, B. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501507102 · Cited by 682
Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery
Landen, C. N., Chavez-Reyes, A., Bucana, C., Schmandt, R., Deavers, M. T., Lopez-Berestein, G., & Sood, A. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0530 · Cited by 675
Frank-Kamenetsky, M., Grefhorst, A., Anderson, N. N., Racie, T. S., Bramlage, B., Akinc, A., Butler, D., Charisse, K., Dorkin, R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 642
Dalby, B. (2004) · Methods · doi:10.1016/j.ymeth.2003.11.023 · Cited by 619
Hu-Lieskovan, S., Heidel, J. D., Bartlett, D. W., Davis, M. E., & Triche, T. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0565 · Cited by 567
Kinetic Characterization of Ribonuclease-Resistant 2′-Modified Hammerhead Ribozymes
Pieken, W. A., Olsen, D. B., Benseler, F., Aurup, H., & Eckstein, F. (1991) · Science · doi:10.1126/science.1857967 · Cited by 463
Synthetic shRNAs as potent RNAi triggers
Siolas, D., Lerner, C., Burchard, J., Ge, W., Linsley, P. S., Paddison, P. J., Hannon, G. J., & Cleary, M. A. (2005) · Nature Biotechnology · doi:10.1038/nbt1052 · Cited by 445
Kawasaki, A. M., Casper, M. D., Freier, S. M., Lesnik, E. A., Zounes, M. C., Cummins, L. L., Gonzalez, C., & Cook, P. D. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00059a007 · Cited by 438
Therapeutic siRNA: principles, challenges, and strategies.
Gavrilov, K., & Saltzman, W. M. (2012) · PubMed Central · Cited by 419
Functional Anatomy of a dsRNA Trigger
Parrish, S., Fleenor, J., Xu, S., Mello, C., & Fire, A. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00106-4 · Cited by 400
A new cationic liposome reagent mediating nearly quantitative transfection of animal cells.
Rose, J. K., Buonocore, L., & Whitt, M. A. (1991) · PubMed · Cited by 385
Corneal Neovascularization: An Anti-VEGF Therapy Review
Chang, J.-H., Garg, N. K., Lunde, E., Han, K.-Y., Jain, S., & Azar, D. T. (2012) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.01.007 · Cited by 381
A review of nanocarriers for the delivery of small interfering RNA
Kesharwani, P., Gajbhiye, V., & Jain, N. K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.06.068 · Cited by 368
NADPH Oxidases of the Brain: Distribution, Regulation, and Function
Infanger, D. W., Sharma, R. V., & Davisson, R. L. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.1583 · Cited by 362
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo
Takeshita, F., Minakuchi, Y., Nagahara, S., Honma, K., Sasaki, H., Hirai, K., Teratani, T., Namatame, N., Yamamoto, Y., Hanai, K., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501753102 · Cited by 355
RNA interference and chemically modified small interfering RNAs
Manoharan, M. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.10.007 · Cited by 346
Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells
Lorenz, C., Hadwiger, P., John, M., Vornlocher, H.-P., & Unverzagt, C. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.07.018 · Cited by 338
2′-O-methyl-modified RNAs Act as TLR7 Antagonists
Robbins, M., Judge, A., Liang, L., McClintock, K., Yaworski, E., & MacLachlan, I. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300240 · Cited by 336
Circumventing Tumor Resistance to Chemotherapy by Nanotechnology
Liang, X.-J., Chen, C., Zhao, Y., & Wang, P. C. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_21 · Cited by 330
Specific and potent RNAi in the nucleus of human cells
Robb, G. B., Brown, K. M., Khurana, J., & Rana, T. M. (2005) · Nature Structural & Molecular Biology · doi:10.1038/nsmb886 · Cited by 311
Engineering RNA for Targeted siRNA Delivery and Medical Application
Guo, P., Coban, O., Snead, N. M., Trebley, J., Hoeprich, S., Guo, S., & Shu, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.008 · Cited by 300
RNA interference using boranophosphate siRNAs: structure-activity relationships
Hall, A. H. S. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh936 · Cited by 285
Rodriguez-Lebron, E., Denovan-Wright, E. M., Nash, K., Lewin, A. S., & Mandel, R. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.05.006 · Cited by 275
First-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin Disorder
Leachman, S. A., Hickerson, R. P., Schwartz, M. E., Bullough, E. E., Hutcherson, S. L., Boucher, K. M., Hansen, C. D., Eliason, M. J., Srivatsa, G. S., Kornbrust, D. J., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.273 · Cited by 265
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy
Gulino, A. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s23696 · Cited by 258
Non-coding RNAs with essential roles in neurodegenerative disorders
Salta, E., & De Strooper, B. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70286-1 · Cited by 243
Martínez, M. A., Gutiérrez, A., Armand-Ugón, M., Blanco, J., Parera, M., Gómez, J., Clotet, B., & Esté, J. A. (2002) · AIDS · doi:10.1097/00002030-200212060-00002 · Cited by 239
Mechanisms of Protein Seeding in Neurodegenerative Diseases
Walker, L. C., Diamond, M. I., Duff, K. E., & Hyman, B. T. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1453 · Cited by 226
Chen, Y., Bathula, S. R., Li, J., & Huang, L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.125906 · Cited by 216
Sustained effects of nonallele‐specific Huntingtin silencing
Drouet, V., Perrin, V., Hassig, R., Dufour, N., Auregan, G., Alves, S., Bonvento, G., Brouillet, E., Luthi‐Carter, R., Hantraye, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21569 · Cited by 216
Ui-Tei, K., Naito, Y., Zenno, S., Nishi, K., Yamato, K., Takahashi, F., Juni, A., & Saigo, K. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn042 · Cited by 176
Safety and Short-Term Toxicity of a Novel Cationic Lipid Formulation for Human Gene Therapy
San, H., Yang, Z.-Y., Pompili, V. J., Jaffe, M. L., Plautz, G. E., Xu, L., Felgner, J. H., Wheeler, C. J., Felgner, P. L., Gao, X., et al. (1993) · Human Gene Therapy · doi:10.1089/hum.1993.4.6-781 · Cited by 174
Harnessing in vivo siRNA delivery for drug discovery and therapeutic development
Xie, F. Y., Woodle, M. C., & Lu, P. Y. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03668-8 · Cited by 174
Silencing of human α-synuclein in vitro and in rat brain using lentiviral-mediated RNAi
Sapru, M. K., Yates, J. W., Hogan, S., Jiang, L., Halter, J., & Bohn, M. C. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2005.12.024 · Cited by 173
Krönke, J., Kittler, R., Buchholz, F., Windisch, M. P., Pietschmann, T., Bartenschlager, R., & Frese, M. (2004) · Journal of Virology · doi:10.1128/jvi.78.7.3436-3446.2004 · Cited by 172
RNA Interference and Cancer Therapy
Wang, Z., Rao, D. D., Senzer, N., & Nemunaitis, J. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0604-5 · Cited by 167
RNAi-based nanomedicines for targeted personalized therapy
Daka, A., & Peer, D. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.014 · Cited by 167
Chapter 10 The Cancer Cell–Leukocyte Fusion Theory of Metastasis
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)00410-7 · Cited by 166
Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs
Boudreau, R. L., Monteys, A. M., & Davidson, B. L. (2008) · RNA · doi:10.1261/rna.1062908 · Cited by 163
Targeted Delivery Systems for Oligonucleotide Therapeutics
Yu, B., Zhao, X., Lee, L. J., & Lee, R. J. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9096-1 · Cited by 158
Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed
McLeod, H. L. (2013) · Science · doi:10.1126/science.1234139 · Cited by 156
Stability Study of Unmodified siRNA and Relevance to Clinical Use
Hickerson, R. P., Vlassov, A. V., Wang, Q., Leake, D., Ilves, H., González-González, E., Contag, C. H., Johnston, B. H., & Kaspar, R. L. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0149 · Cited by 146
Self-citationRNA interference therapeutics for cancer: Challenges and opportunities (Review)
Bora, R. S., Gupta, D., Mukkur, T. K. S., & Saini, K. S. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.871 · Cited by 141
Viral vector-mediated RNA interference
Couto, L. B., & High, K. A. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.06.007 · Cited by 139
An RNA Alternative to Human Transferrin: A New Tool for Targeting Human Cells
Wilner, S. E., Wengerter, B. C., Maier, K. E., Magalhães, M. D. L. B., del Amo, D. S., Pai, S., Opazo, F., Rizzoli, S. O., Yan, A. C., & Levy, M. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.14 · Cited by 139
miRNA-Based Therapeutic Strategies
Ishida, M., & Selaru, F. M. (2012) · Current Pathobiology Reports · doi:10.1007/s40139-012-0004-5 · Cited by 134
Friend or foe: the role of microRNA in chemotherapy resistance
Li, H., & Yang, B. B. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.35 · Cited by 131
Chong, R. H. E., González-González, E., Lara, M. F., Speaker, T. J., Contag, C. H., Kaspar, R. L., Coulman, S. A., Hargest, R., & Birchall, J. C. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.12.030 · Cited by 122
Fukuhara, T., Kambara, H., Shiokawa, M., Ono, C., Katoh, H., Morita, E., Okuzaki, D., Maehara, Y., Koike, K., & Matsuura, Y. (2012) · Journal of Virology · doi:10.1128/jvi.00567-12 · Cited by 121
RNAi-based therapeutic strategies for metabolic disease
Czech, M., Aouadi, M., & Tesz, G. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.57 · Cited by 118
Campochiaro, P. A. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302653 · Cited by 116
Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review
Chaturvedi, K., Ganguly, K., Kulkarni, A. R., Kulkarni, V. H., Nadagouda, M. N., Rudzinski, W. E., & Aminabhavi, T. M. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.610790 · Cited by 114
MicroRNA-182 plays an onco-miRNA role in cervical cancer
Tang, T., Wong, H. K., Gu, W., Yu, M., To, K., Wang, C. C., Wong, Y. F., Cheung, T. H., Chung, T. K. H., & Choy, K. W. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.12.043 · Cited by 110
Self-citationPotential clinical applications of siRNA technique: benefits and limitations
Chen, S., & Zhaori, G. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02400.x · Cited by 107
Hong, C.-S., Goins, W. F., Goss, J. R., Burton, E. A., & Glorioso, J. C. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302719 · Cited by 107
Redox signalling involving NADPH oxidase-derived reactive oxygen species
Dworakowski, R., Anilkumar, N., Zhang, M., & Shah, A. M. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340960 · Cited by 105
Prospects for Treatment of Latent HIV
Barton, K., Burch, B. D., Soriano-Sarabia, N., & Margolis, D. M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.202 · Cited by 101
Lipid-based vectors for siRNA delivery
Zhang, S., Zhi, D., & Huang, L. (2012) · Journal of drug targeting · doi:10.3109/1061186x.2012.719232 · Cited by 95
Malmo, J., Sandvig, A., Vårum, K. M., & Strand, S. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054182 · Cited by 90
Angiotensin AT1 receptor over-expression in hypercholesterolaemia
Strehlow, K., Waßmann, S., Böhm, M., & Nickenig, G. (2000) · Annals of Medicine · doi:10.3109/07853890008995944 · Cited by 85
Liu, J., Gu, C. Y., Cabigas, E. B., Pendergrass, K. D., Brown, M. E., Luo, Y., & Davis, M. E. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.02.008 · Cited by 77
Goodchild, J. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-188-8_1 · Cited by 75
Gene Delivery Systems: Recent Progress in Viral and Non-Viral Therapy
Cevher, E., Demir, A. S., & Çağlar, E. Ş. (2012) · InTech eBooks · doi:10.5772/53392 · Cited by 73
Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy
Tomek, M., Akiyama, T., & Dass, C. R. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01526.x · Cited by 71
Synergistic Silencing: Combinations of Lipid-like Materials for Efficacious siRNA Delivery
Whitehead, K. A., Sahay, G., Li, G. Z., Love, K. T., Alabi, C. A., Ma, M., Zurenko, C., Querbes, W., Langer, R., & Anderson, D. G. (2011) · Molecular Therapy · doi:10.1038/mt.2011.141 · Cited by 70
Vlassov, A. V., Korba, B. E., Farrar, K., Mukerjee, S., Seyhan, A. A., Ilves, H., Kaspar, R. L., Leake, D., Kazakov, S. A., & Johnston, B. H. (2007) · Oligonucleotides · doi:10.1089/oli.2006.0069 · Cited by 63
Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy
Dou, S., Yao, Y., Yang, X., Sun, T., Mao, C., Song, E., & Wang, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.015 · Cited by 52
Xue, B., Beltz, T. G., Johnson, R. F., Guo, F., Hay, M., & Johnson, A. K. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00873.2011 · Cited by 48
Non-viral vectors for the mediation of RNAi
Zhang, S., Zhao, Y., Zhi, D., & Zhang, S. (2011) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2011.07.005 · Cited by 47
Matokanović, M., Barišić, K., Filipović‐Grčić, J., & Maysinger, D. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.04.001 · Cited by 46
Synthesis of carbamate-linked lipids for gene delivery
Liu, D., Hu, J., Qiao, W., Li, Z., Zhang, S., & Cheng, L. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.04.010 · Cited by 45
Lara, M. F., González-González, E., Speaker, T. J., Hickerson, R. P., Leake, D., Milstone, L. M., Contag, C. H., & Kaspar, R. L. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.211 · Cited by 45
GnT-V, macrophage and cancer metastasis: A common link
Chakraborty, A. K., & Pawelek, J. M. (2003) · Clinical & Experimental Metastasis · doi:10.1023/a:1024007915938 · Cited by 44
Zhang, B., & Mallapragada, S. K. (2010) · Acta Biomaterialia · doi:10.1016/j.actbio.2010.11.033 · Cited by 42
Transporting silence: Design of carriers for siRNA to angiogenic endothelium
Schiffelers, R. M., Mixson, A. J., Ansari, A. M., Fens, M. H. A. M., Tang, Q., Zhou, Q., Xu, J., Molema, G., Lu, P. Y., Scaria, P. V., et al. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.05.018 · Cited by 41
Synthesis and characterization of a series of carbamate‐linked cationic lipids for gene delivery
Liu, D., Hu, I., Qiao, W., Li, Z., Zhan, S., & Cheng, L. (2005) · Lipids · doi:10.1007/s11745-005-1446-5 · Cited by 34
Induction of apoptosis by chitosan/HPV16 E7 siRNA complexes in cervical cancer cells
Yang, J., LI, S., Guo, F., Zhang, W., WANG, Y., & Pan, Y. H. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.1246 · Cited by 32
Stessl, M., Marchetti‐Deschmann, M., Winkler, J., Lachmann, B., Allmaier, G. M., & Noe, C. R. (2009) · Journal of Proteomics · doi:10.1016/j.jprot.2009.06.001 · Cited by 29
Niu, Z., Li, X., Hu, B., Li, R., Wang, L., Wu, L., & Wang, X. (2012) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms091 · Cited by 29
Downregulation of the GnT-V gene inhibits metastasis and invasion of BGC823 gastric cancer cells
HUANG, B., Sun, L., Cao, J., ZHANG, Y., Wu, Q., Zhang, J., GE, Y., Fu, L., & Wang, Z. (2013) · Oncology Reports · doi:10.3892/or.2013.2373 · Cited by 28
Motavaf, M., Safari, S., & Alavian, S. M. (2012) · Journal of Viral Hepatitis · doi:10.1111/jvh.12006 · Cited by 26
RNA interference remarkably suppresses bcl-2 gene expression in cancer cells in vitro and in vivo
Fu, G., Lin, X.-H., Han, Q.-W., Xu, Y., Guo, D., Xu, G., & Hou, Y. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.8.1889 · Cited by 26
Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles
Zhang, Q., & Li, F. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319370009 · Cited by 25
Lentivirus-Expressed siRNA Vectors Against Alzheimer Disease
Peng, K. A., & Masliah, E. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-533-0_15 · Cited by 24
RNA Interference as a Plausible Anticancer Therapeutic Tool
Ramachandran, P. V., & Savarimuthu Ignacimuthu, S. J. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.6.2445 · Cited by 23
In Vitro and In Vivo Inhibition of MRP Gene Expression and Reversal of Multidrug Resistance by siRNA
Wu, Z., Li, X., Zeng, Y., Zhuang, X., Shen, H., Zhu, H., Liu, H., & Xiao, H. (2010) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2010.00642.x · Cited by 21
Spelios, M. G., Nedd, S., Matsunaga, N., & Savva, M. (2007) · Biophysical Chemistry · doi:10.1016/j.bpc.2007.05.016 · Cited by 19
The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer
Fakih, M. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/era.13.20 · Cited by 18
Shi, Y., Tong, M.-M., Wu, Y., Yang, Z., Hoffman, R. M., Zhang, Y., Tian, Y., Qi, M.-M., Lin, Y., Liu, Y., et al. (2013) · PubMed · Cited by 17
Cited by
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
Targeted Protein Degradation: from Chemical Biology to Drug Discovery
Cromm, P. M., & Crews, C. M. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.05.024 · Cited by 412
RNAi-based therapeutics and tumor targeted delivery in cancer
Kara, G., Calin, G. A., & Ozpolat, B. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114113 · Cited by 411
Synthesis, Characterization, and Applications of Metal Nanoparticles
Shnoudeh, A. J., Hamad, I., Abdo, R. W., Qadumii, L., Jaber, A. Y., Surchi, H. S., & Alkelany, S. Z. (2019) · Biomaterials and Bionanotechnology · doi:10.1016/b978-0-12-814427-5.00015-9 · Cited by 309
Nano-based delivery of RNAi in cancer therapy
Xin, Y., Huang, M., Guo, W. W., Huang, Q., Zhang, L. Z., & Jiang, G. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0683-y · Cited by 295
Metadata
- Authors
- Deng, Y., Wang, C. C., Choy, K. W., Du, Q., Chen, J., Wang, Q., Li, L., Chung, T. K. H., & Tang, T.
- Venue
- Gene
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 538
- Issue
- 2
- Pages
- 217-227
- ISSN
- 0378-1119 (ISSN-L)
- OpenAlex
- W2035110063
- Cited by
- 301
- References
- 121
- FWCI
- 15.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.